NPM-115
Type 2 Diabetes (proof-of-concept)
Phase 1 CompletedUsed in LIBERATE-1 trial
Key Facts
Indication
Type 2 Diabetes (proof-of-concept)
Phase
Phase 1 Completed
Status
Used in LIBERATE-1 trial
Company
About Vivani Medical
Vivani Medical aims to revolutionize chronic disease treatment by eliminating adherence challenges through its miniaturized, subdermal drug implants. The company's NanoPortal™ technology has been validated in a successful Phase 1 trial (LIBERATE-1) and is now being applied to a pipeline focused on GLP-1 agonists for obesity and type 2 diabetes. With a veteran leadership team and a public listing on NASDAQ, Vivani is positioned to advance its long-acting implant solutions through clinical development.
View full company profile